Supreme Court Rules Stem Cell Therapy for Autism Can Only Be Administered in Approved Clinical Trials

Introduction

In a landmark judgment delivered on January 30, 2026, the Supreme Court of India has ruled that offering stem cell therapy (SCT) as a routine clinical treatment for Autism Spectrum Disorder (ASD) constitutes professional malpractice due to the lack of scientific evidence supporting its efficacy and safety. A bench comprising Justices J.B. Pardiwala and R. Mahadevan emphasized that such therapies must be confined to approved and monitored clinical trials to protect patients from unethical practices. The decision came in the public interest litigation Yash Charitable Trust & Ors. v. Union of India & Ors. (W.P.(C) No. 369/2022), where petitioners, including an NGO focused on developmental disabilities and medical ethics advocates, sought enforcement of existing regulations against the rampant promotion of unproven SCT for ASD by various clinics across India. The ruling underscores the court's commitment to upholding medical ethics, informed consent, and the standard of care owed by practitioners, while directing the Ministry of Health and Family Welfare (MoHFW) to ensure continuity for ongoing patients and consolidate regulatory guidelines. This verdict not only addresses immediate concerns but also signals a need for clearer legislative frameworks in emerging medical fields like stem cell research.

The judgment, spanning 99 pages and cited, responds to growing reports of clinics charging exorbitant fees—often lakhs of rupees—for SCT, preying on desperate families seeking cures for ASD, a neurodevelopmental disorder with no known definitive treatment beyond behavioral and supportive therapies. By invoking principles from precedents like V.P. Shantha and Samira Kohli , the court clarified that patient autonomy does not extend to demanding unproven treatments lacking adequate informational basis. While prohibiting commercial SCT, the decision preserves avenues for ethical research, potentially guiding future advancements in ASD management.

Case Background

The writ petition, filed in May 2022 under Article 32 of the Constitution, was initiated by Yash Charitable Trust, an NGO based in Mumbai dedicated to supporting individuals with intellectual and developmental disabilities; Dr. Vibha Krishnamurthy, a developmental pediatrician with expertise in child rights and ASD; the Forum for Medical Ethics Society; and K.S. Ganpathy, a parent whose child underwent SCT in 2011. The petitioners highlighted the unchecked proliferation of clinics offering SCT as a "cure" for ASD, despite international and national guidelines deeming it unproven. ASD, characterized by challenges in communication, socialization, and repetitive behaviors, affects millions in India, with families often turning to alternative therapies amid limited access to evidence-based interventions like occupational or speech therapy.

The dispute arose from the petitioners' contention that SCT's commercial administration violates the Drugs and Cosmetics Act, 1940 (Drugs Act), the New Drugs and Clinical Trials Rules, 2019 (NDCT Rules), and guidelines from the Indian Council of Medical Research (ICMR), including the National Guidelines for Stem Cell Research, 2017 (NGSCR 2017). They provided evidence of over 59 entities engaged in such practices, as noted in a 2017 Lok Sabha response, and argued that desperate parents, unaware of the experimental nature of SCT, were being exploited financially without trial safeguards like compensation for adverse events.

Respondents included the Union of India (through MoHFW), National Medical Commission (NMC), ICMR, and specific clinics like Neurogen Brain and Spine Institute Pvt. Ltd., Reelabs Pvt. Ltd., and Saffron Naturale Products Ltd., impleaded for their alleged involvement. The Parents’ Forum for Stem Cells in Autism and Cerebral Palsy intervened in support of continued access to autologous SCT, citing anecdotal improvements in their children.

The case timeline reflects evolving regulations: Post-filing, the Ethics and Medical Registration Board (EMRB) of NMC issued recommendations on December 6, 2022, deeming SCT promotion for ASD as professional misconduct. The ICMR's Evidence Based Status of Stem Cell Therapy for Human Diseases, 2021 (EBSSCT 2021), reinforced that SCT lacks evidence beyond supportive therapies. A related Delhi High Court interim order in Dalip Kaur v. Union of India (W.P.(C) No. 6850/2023) allowed ongoing treatments pending adjudication, emphasizing patient autonomy but at the patients' own risk. The Supreme Court listed the matter multiple times, incorporating these developments, and framed two key issues: (1) the legality of offering SCT as routine healthcare, and (2) the regulatory framework under the Drugs Act and NDCT Rules for ASD-related stem cell research.

This PIL, maintainable as it addressed public health concerns without personal vendettas, exposed a regulatory gray area exploited by clinics, leading to the court's comprehensive analysis of medical negligence, consent, and biomedical research ethics.

Arguments Presented

The petitioners, represented by advocate Siddharth Nath, argued that SCT for ASD contravenes NDCT Rules, particularly Rule 74 prohibiting unapproved new drug manufacture and Rule 91 requiring clinical trial permissions. They stressed that SCT, often autologous bone marrow-derived, qualifies as a "new drug" under Rule 2(1)(w)(v) as a "stem cell derived product," necessitating Central Licensing Authority (CLA) approval from the Central Drugs Standard Control Organisation (CDSCO). Without trials, patients lack protections under Chapter VI, such as injury compensation. Citing ICMR's NGSCR 2017 and EBSSCT 2021, they noted SCT's unethical status outside trials, with EMRB-NMC recommendations labeling its promotion as misconduct. The petitioners distinguished ICMR-approved products like 'Stempeucel' (for other conditions) from ASD SCT and urged enforcement against clinics violating the Drugs Act, emphasizing exploitation of vulnerable families paying "extortionate sums" for false hopes.

The Union of India, via Additional Solicitors General Vikramjit Banerjee and Aishwarya Bhati, clarified that while "stem cell derived products" (involving substantial manipulation) are "new drugs" under NDCT Rules, autologous SCT for ASD—limited to minimal processing like rinsing—falls outside this, as per a February 9, 2021, MoHFW clarification under Section 33P of the Drugs Act. They referenced DTAB's 84th meeting (August 27, 2019) exempting non-commercial routine therapies from Drugs Act purview and aligned with ICMR/ICMR-DHR documents advising against routine SCT for ASD. However, they acknowledged no specific provisions regulate "therapies" versus "products," deferring to ICMR guidelines for ethical oversight, and noted the dissolution of the National Apex Committee for Stem Cell Research and Therapy (NAC-SCRT) in March 2024, shifting review to institutional Ethics Committees (ECs) with stem cell experts.

The NMC, through counsel Prateek Bhatia, endorsed EMRB's 2022 recommendations, based on ICMR's evidence review concluding insufficient proof for SCT in ASD. They affirmed that violations constitute misconduct under National Medical Commission Registered Medical Practitioner (Professional Conduct) Regulations, 2023, actionable by State Medical Councils, and highlighted MoHFW's non-approval of ASD SCT.

Clinic respondents, like Neurogen (via Utkarsh Sharma), defended autologous SCT as a "procedure" not a "drug," citing minimal manipulation and state approvals (e.g., Maharashtra's February 2024 order). They relied on DTAB recommendations and a purported 2022 MoHFW list categorizing bone marrow SCT as a "clinical option" for autism, arguing NGSCR 2017 lacks binding force as mere guidance. Reelabs (Nikilesh Ramachandran) denied ASD-specific advertising, focusing on ICMR-approved cord blood banking for 80 disorders excluding ASD. Saffron Naturale (senior counsel Swarupama Chaturvedi) positioned itself as a processor, not treater, unbound by end-use regulations.

The Parents’ Forum (Nitesh Ranjan), representing families, invoked Article 21's right to life and health, claiming SCT improvements via medical records. They echoed clinics' distinctions between products and therapies, supported Delhi High Court orders permitting continuations, and argued consent overrides risks, warning that bans deprive access to beneficial autologous interventions using patients' own cells.

These arguments crystallized the tension between ethical regulation, scientific evidence, and patient desperation, with petitioners prioritizing safeguards and respondents defending access under autonomy claims.

Legal Analysis

The Supreme Court's reasoning rooted in medical negligence jurisprudence, beginning with the "Bolam Test" adopted in Indian Medical Association v. V.P. Shantha (1995) 6 SCC 651, which holds practitioners liable if deviating from practices accepted by a competent body of professionals, judged by knowledge at the time ( Jacob Mathew v. State of Punjab , (2005) 6 SCC 1). Reaffirmed in M.A. Biviji v. Sunita (2024) 2 SCC 242, the court stressed that negligence requires duty breach causing harm, but professionals are shielded if following "sound and relevant medical practice" based on contemporary evidence—not perfection. For SCT, lacking empirical support, offering it routinely falls below this standard, as ICMR documents (NGSCR 2017, EBSSCT 2021) deem it unethical outside trials, warning of "therapeutic misconception" where patients expect routine care benefits from experimental procedures.

Distinguishing "drugs" under Section 3(b)(i) of the Drugs Act (broadly including treatment substances like stem cells) from "new drugs" under NDCT Rule 2(1)(w)(v) (stem cell-derived products with substantial manipulation), the court clarified autologous SCT for ASD isn't a "new drug" but still a "drug," attracting protections. Routine administration violates Rule 74's unapproved manufacture ban. For research, Chapter IV NDCT Rules govern non-"new drug" stem cells as "biomedical health research," binding ICMR's National Ethical Guidelines (Clauses 4.2.4, 7.9.1) via Rules 15-16(4), mandating clinical trials except for hematopoietic transplants. Violations trigger IMC Regulations 2002 (Regulation 7.22) misconduct, continuing under NMC Act Section 61(2).

On consent, Samira Kohli v. Dr. Prabha Manchanda (2008) 2 SCC 1 requires "adequate information" (nature, risks, alternatives) for validity; absent for unproven SCT, choices under misconception aren't binding ( Common Cause v. Union of India , (2018) 5 SCC 1). Autonomy allows trial participation but not demanding unethical treatments. The court invalidated DTAB's unadopted 2019 recommendations exempting non-commercial therapies and a purported MoHFW list, prioritizing ICMR's evidence-based stance.

Precedents like Laxman Balkrishna Joshi v. Trimbak Bapu Godbole (1969) 1 SCR 206 outlined duties (care in undertaking, deciding, administering treatment), while Kusum Sharma v. Batra Hospital (2010) 3 SCC 480 clarified no negligence for genuine opinion differences if reasonable. Here, uniform ICMR/NMC consensus against routine SCT distinguishes it from defensible variance. The ruling harmonizes Drugs Act/NDCT with ethics, urging consolidation amid NAC-SCRT dissolution (March 2024 Order conflicting Rules 17-18; held non est per Jaiveer Singh v. State of Uttarakhand , 2024 SCC OnLine SC 1066). Implications include disciplinary actions under NMC Act Section 27 and Clinical Establishments Act Sections 32/40, deterring commercialization.

This analysis bridges negligence, consent, and regulation, ensuring evidence-based medicine prevails over exploitation.

Key Observations

The judgment features pivotal excerpts emphasizing ethical imperatives:

• On standard of care: "A medical practitioner cannot be said to meet the standard of reasonable care if they administer an intervention that lacks credible scientific evidence of safety and efficacy, or where authoritative medical bodies unequivocally state that such form of treatment is not recommended." (Para 63, drawing from M.A. Biviji and V.P. Shantha ).

• On ICMR guidelines' role: "These documents indicate that the therapeutic use of stem cells for the treatment of ASD is not recognized as a sound and relevant medical practice due to the lack of scientific support and empirical evidence regarding its efficacy. It is categorically mentioned therein that any stem cell use in patients must only be done within the purview of an approved and monitored clinical trial... every use of stem cells in patients outside an approved clinical trial is unethical and shall be considered as malpractice." (Para 90, referencing NGSCR 2017 and EBSSCT 2021).

• On consent and autonomy: "We are of the considered view that a treatment cannot be demanded by a patient as a matter of right... adequate information as regards a particular treatment, is the bedrock and the consent thereto should be on the basis of such adequate information. It is undisputed that stem cell therapy for treatment of ASD does not fulfil the essentials of 'adequate information'." (Para 96, citing Samira Kohli ).

• On regulatory pathway: "All stem cell research involving human participants must necessarily be in a clinical trial setting." (Para 120, enforcing National Ethical Guidelines via NDCT Rules).

• On consequences: "Medical practitioners who offer such stem cell therapy as a routine clinical service... could be said to be failing to meet the reasonable 'standard of care' owed by them towards the patients." (Para 70, linking to professional misconduct).

These quotes, attributed to the bench, encapsulate the ruling's ethical and legal core, highlighting protection against unproven interventions.

Court's Decision

The Supreme Court conclusively held that stem cell therapy for ASD cannot be offered as a routine clinical service, deeming it malpractice and professional misconduct outside approved clinical trials. Medical practitioners failing this standard risk liability under medical negligence laws and NMC regulations, with clinics facing registration cancellation under the Clinical Establishments Act, 2010. The court mandated SCT only in monitored trial settings: for "stem cell-derived products" (substantial manipulation), via NDCT Rules' new drug clinical trials with CLA/CDSCO approval; for minimally processed autologous cells, as biomedical research under Chapter IV, bound by ICMR Ethical Guidelines requiring EC/IC-SCR approval and trial format.

Practical effects include immediate curbs on commercial SCT, safeguarding ASD patients from false hopes and financial exploitation—clinics must cease promotion/advertising, with State Medical Councils investigating violations. For ongoing patients, the court directed MoHFW's Secretary, consulting AIIMS and NMC, to devise continuity solutions, re-routing to trial institutions within four weeks, filing compliance report. This prevents abrupt harm while enforcing ethics.

Broader implications: The ruling compels MoHFW to consolidate fragmented guidelines into coherent legislation, reinstating NAC-SCRT or equivalent for oversight, addressing ambiguities like DHR's role (restored via NDCT Rules). Future cases may see stricter scrutiny of experimental therapies (e.g., gene editing), bolstering informed consent in vulnerable populations. By prioritizing evidence over autonomy in unproven contexts, it deters "predatory marketing" (as noted in sources like ETV Bharat), potentially reducing ASD misinformation and fostering ethical research. Compliance within four weeks ensures minimal disruption, with the matter relisted for final directions. This decision fortifies India's biomedical regulatory landscape, balancing innovation with patient safety.